Asabys leads €20m round for Anaconda Biomed

Alessia Argentieri
04 December 2019

Tweet
Facebook
LinkedIn
Google plus
Send to

Banco Sabadell-backed Asabys Partners, a Spanish venture capital house, has led a €20m funding round for Barcelona-based medical device startup Anaconda Biomed.

Previous backers Ysios Capital, Sabadell Venture Capital, Innogest and Omega Funds also took part in the round, alongside 80% of the company's staff. This new round brings the total funding raised by Anaconda close to €40m.

Asabys invested via its first fund, Sabadell Asabys Health Innovation Investments, a biotechnology-dedicated vehicle launched with a €80m target that is currently fundraising. The fund has Banco Sabadell as an anchor investor.

Following the deal, Asabys's founding partner, Josep Lluís Sanfeliu, and investment director Sylvain Sachot will join Anaconda's board.

The company intends to use the fresh financing to fund a clinical trial and obtain EMA and FDA approval.

Previous funding
Anaconda raised an initial seed round from Italian venture capital house Innogest in May 2016.

Subsequently, Omega, Innogest, Ysios and Banco Sabadell invested €15m in a series-A round for the company in May 2017.

The company received an additional investment of an undisclosed amount in January 2018 from Banco Sabadell's platform BStartup.

Company
Established in 2014 and based in Barcelona, Anaconda develops a new generation of catheters to perform mechanical thrombectomies. It claims its ANCD Advanced Thrombectomy System is able to restore blood flow in patients experiencing acute ischemic stroke due to a large vessel neurovascular occlusion and improve the percentages of total recovery. Anaconda Biomed has already enrolled 14 patients in a 125-patient, first-in-human study.

People
Anaconda Biomed – François Salmon (CEO); Marc Ribo, Ofir Arad (co-founders).
Asabys Partners – Josep Lluís Sanfeliu (founding partner); Sylvain Sachot (investment director).